Loading stock data…
ADAG
$3.82+0.14 (+3.80%)
Market ClosedLast close May 1
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adagene Inc. in the Healthcare sector is trading at $3.82. The stock is currently 20% below its 52-week high of $4.75, remaining 55.9% above its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why ADAG maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.82
Potential Upside
5%
Whystock Fair Value$4.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$248.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.82%
Volume
Today's trading volume
150,134
Recent News
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study […]
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed?
In late March and early April 2026, Incyte reported positive 54-week Phase 3 data for its JAK1 inhibitor povorcitinib in hidradenitis suppurativa and Adagene announced entering a clinical collaboration with Incyte to test a combination immunotherapy regimen in advanced microsatellite stable colorectal cancer. Together with recent leadership changes, these developments highlight Incyte’s push to build a broader immunology and oncology franchise around both late-stage and early pipeline...
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon
Adagene (NASDAQ:ADAG) outlined its clinical and strategic priorities at Leerink Partners’ global healthcare conference, with Chief Strategy Officer Mickael Chane-Du focusing primarily on the company’s lead program, ADG126, and its progress in metastatic microsatellite-stable colorectal cancer (MSS C
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk
Adagene (NASDAQ:ADAG) highlighted updated details around its lead immuno-oncology program, ADG126, during an Oppenheimer discussion featuring Chief Strategy Officer Mickael Chane-Du. The company is developing ADG126 as a “masked” anti-CTLA-4 antibody intended to improve the safety of CTLA-4 blockade
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.